Monica Moya

Dr. Monica Moya

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
WHW. F. Hynes
W. F. Hynes
MPM. Pepona
M. Pepona
CRC. Robertson
C. Robertson
JAJ. Alvarado
J. Alvarado
KDK. Dubbin
K. Dubbin
MMMonica Moya
Monica Moya
3D printed vasculature paired with a 3D in silico model interrogates biophysical forces of circulating tumor cells.

18 November 2019 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
MMMonica Moya
Monica Moya
MTMichael Triplett
Michael Triplett
MSMelinda Simon
Melinda Simon
JAJavier Alvarado
Javier Alvarado
RBRoss Booth
Ross Booth
EWElizabeth K. Wheeler
Elizabeth K. Wheeler

14 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NHNicholas Hum
Nicholas Hum
ASAimy Sebastian
Aimy Sebastian
SGSean Gilmore
Sean Gilmore
WHWei He
Wei He
KMKelly Martin
Kelly Martin
Gabriela G LootsGabriela G Loots
Gabriela G Loots
Current pre-clinical models of cancer fail to recapitulate the cancer cell behavior in primary tumors primarily because of the lack of a deeper understanding of the effects that the microenvironment has on cancer cell phenotype. Transcriptomic profiling of 4T1 murine mammary carcinoma cells from 2D and 3D cultures, subcutaneous or orthotopic allografts (from immunocompetent or immunodeficient mice), as well as ex vivo tumoroids, revealed differences in molecular signatures including altered expression of genes involved in cell cycle progression, cell signaling and extracellular matrix remodeling. The 3D culture platforms had more in vivo-like transcriptional profiles than 2D cultures. In vivo tumors had more cells undergoing epithelial-to-mesenchymal transition (EMT) while in vitro cultures had cells residing primarily in an epithelial or mesenchymal state. Ex vivo tumoroids incorporated aspects of in vivo and in vitro culturing, retaining higher abundance of cells undergoing EMT while shifting cancer cell fate towards a more mesenchymal state. Cellular heterogeneity surveyed by scRNA-seq revealed that ex vivo tumoroids, while rapidly expanding cancer and fibroblast populations, lose a significant proportion of immune components. This study emphasizes the need to improve in vitro culture systems and preserve syngeneic-like tumor composition by maintaining similar EMT heterogeneity as well as inclusion of stromal subpopulations.

1 November 2013 in Microvascular Research
Verified
Journal Article
Closed access
OKOmaditya Khanna
Omaditya Khanna
JHJung-Ju Huang
Jung-Ju Huang
MMMonica Moya
Monica Moya
CWChih-Wei Wu
Chih-Wei Wu
MCMing-Huei Cheng
Ming-Huei Cheng
Eric M. BreyEric M. Brey
Eric M. Brey

10 May 2021 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
EWElisa M. Wasson
Elisa M. Wasson
KDKaren Dubbin
Karen Dubbin
MMMonica Moya
Monica Moya
Interest in recapitulating in vivo phenomena in vitro using organ-on-a-chip technology has grown rapidly and with it, attention to the types of fluid flow experienced in the body has followed suit. These platforms offer distinct advantages over in vivo models with regards to human relevance, cost, and control of inputs (e.g., controlled manipulation of biomechanical cues from fluid perfusion). Given the critical role biophysical forces play in several tissues and organs, it is therefore imperative that engineered in vitro platforms capture the complex, unique flow profiles experienced in the body that are intimately tied with organ function. In this review, we outline the complex and unique flow regimes experienced by three different organ systems: blood vasculature, lymphatic vasculature, and the intestinal system. We highlight current state-of-the-art platforms that strive to replicate physiological flows within engineered tissues while introducing potential limitations in current approaches.

31 May 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
EWElisa Marie Wasson
Elisa Marie Wasson
WHWei He
Wei He
JAJesse Ahlquist
Jesse Ahlquist
WHWilliam Fredrick Hynes
William Fredrick Hynes
MTMichael Gregory Triplett
Michael Gregory Triplett
EWElizabeth K. Wheeler
Elizabeth K. Wheeler
There is an urgent need to develop new therapies for colorectal cancer that has metastasized to the liver and, more fundamentally, to develop improved preclinical platforms of colorectal cancer liver metastases (CRCLM) to screen therapies for efficacy. To this end, we developed a multi-well perfusable bioreactor capable of monitoring CRCLM patient-derived organoid response to a chemotherapeutic gradient. CRCLM patient-derived organoids were cultured in the multi-well bioreactor for 7 days and the subsequently established gradient in 5-fluorouracil (5-FU) concentration resulted in a lower IC50 in the region near the perfusion channel versus the region far from the channel. We compared behaviour of organoids in this platform to two commonly used PDO culture models: organoids in media and organoids in a static (no perfusion) hydrogel. The bioreactor IC50 values were significantly higher than IC50 values for organoids cultured in media whereas only the IC50 for organoids far from the channel were significantly different than organoids cultured in the static hydrogel condition. Using finite element simulations, we showed that the total dose delivered, calculated using area under the curve (AUC) was similar between platforms, however normalized viability was lower for the organoid in media condition than in the static gel and bioreactor. Our results highlight the utility of our multi-well bioreactor for studying organoid response to chemical gradients and demonstrate that comparing drug response across these different platforms is nontrivial.